Grasustek (Pegfilgrastim)

Grasustek is indicated for the prophylaxis of neutropenia associated with myelosuppressive chemotherapy.

• Reduce the incidence of febrile neutropenia in patients receiving high‑risk chemotherapy regimens.
• Support dose‑dense or dose‑intense chemotherapy protocols by maintaining neutrophil counts.
• Facilitate timely administration of subsequent chemotherapy cycles.
• May be used in patients with solid tumors or hematologic malignancies where neutropenia is a known complication.

The safety profile of pegfilgrastim reflects its pharmacologic activity on neutrophil production; side effects are categorized as common or serious.

Common

• Bone pain, especially in the lower back or hips.
• Injection‑site reactions such as redness, swelling, or mild discomfort.
• Fatigue or generalized weakness.
• Nausea or mild gastrointestinal upset.

Serious

• Splenic rupture or enlargement.
• Acute respiratory distress or severe allergic reactions (anaphylaxis).
• Severe skin reactions like Stevens‑Johnson syndrome.
• Unexplained fever or sepsis despite neutrophil recovery.

Before prescribing Grasustek, clinicians should evaluate patient‑specific factors and monitor for potential risks.

• Assess baseline neutrophil counts; avoid use in patients with severe neutropenia unrelated to chemotherapy.
• Use caution in individuals with a history of splenic disorders or abdominal trauma.
• Monitor for signs of bone pain and provide analgesia as needed.
• Evaluate renal or hepatic impairment, although dose adjustment is generally not required.
• Consider pregnancy status; the drug’s safety in pregnancy is not established.
• Review concurrent use of other myeloid growth factors to prevent overlapping effects.

Pegfilgrastim may interact with other medications or biologics; awareness of these interactions helps optimize safety.

Avoid

• Concurrent use of other granulocyte‑colony stimulating agents (e.g., filgrastim) without clinical justification.
• Live vaccines administered within 2 weeks before or after pegfilgrastim injection.

Use with caution

• Chemotherapy agents that cause profound myelosuppression; timing of pegfilgrastim administration should follow chemotherapy per guidelines.
• Corticosteroids, which may mask bone‑pain symptoms.
• Antimicrobial agents that affect bone‑marrow function, such as certain antimetabolites.